Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Optinose Inc (NQ: OPTN )

0.9253 -0.0047 (-0.51%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 24, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 4,295,326
Open 0.9253
Bid (Size) 1.390 (45)
Ask (Size) 1.400 (22)
Prev. Close 0.9300
Today's Range 0.9253 - 0.9253
52wk Range 0.8550 - 2.100
Shares Outstanding 53,309,012
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Optinose Provides Corporate Update on XHANCE Launch and Outlook and Announces Preliminary First Quarter 2024 XHANCE Net Revenue of $14.9 million
Conference Call and Webcast to be held April 25, 2024, at 10:00 a.m. Eastern Time 
From Optinose, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga

Performance

YTD
-25.98%
-25.98%
1 Month
-38.31%
-38.31%
3 Month
-36.62%
-36.62%
6 Month
-21.92%
-21.92%
1 Year
-47.72%
-47.72%

More News

Read More
Optinose to Present at the Needham Virtual Healthcare Conference
From Optinose, Inc.
Via GlobeNewswire
OptiNose's Earnings: A Preview
Via Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
XHANCE Approved by FDA as First and Only Medication Indicated for Treatment of Adults with Chronic Rhinosinusitis without Nasal Polyps
From Optinose, Inc.
Via GlobeNewswire
OPTN Stock Earnings: OptiNose Meets EPS, Beats Revenue for Q4 2023
Via InvestorPlace
Optinose Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Operational Highlights
From Optinose, Inc.
Via GlobeNewswire
Earnings Scheduled For March 7, 2024
Via Benzinga
Optinose Announces Reporting Date for Fourth Quarter 2023 Financial Results
From Optinose, Inc.
Via GlobeNewswire
Optinose Announces the Publication of ReOpen Phase 3 Clinical Trial Program Evaluating XHANCE in the Journal of Allergy and Clinical Immunology: In Practice
From Optinose, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
Gold Moves Higher; Campbell Soup Earnings Top Expectations
Via Benzinga
Topics Stocks
Exposures US Equities
Why AeroVironment Shares Are Trading Lower By Over 9%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
Crude Oil Down 4%; Pharvaris Shares Spike Higher
Via Benzinga
Topics Stocks
Exposures Fossil Fuels US Equities
US Stocks Higher; Private Payrolls Rise By 103,000 In November
Via Benzinga
Topics Stocks
Exposures US Equities
Why ENT-Focused OptiNose Shares Are Diving Today
Via Benzinga
Exposures Product Safety
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Optinose Announces 3-Month Extension of FDA Review Period for the Supplemental New Drug Application for XHANCE
From Optinose, Inc.
Via GlobeNewswire
Optinose to Present at the 35th Annual Piper Sandler Healthcare Conference
From Optinose, Inc.
Via GlobeNewswire
Optinose Reports Third Quarter 2023 Financial Results and Operational Updates
From Optinose, Inc.
Via GlobeNewswire
Optinose Announces Reporting Date for Third Quarter 2023 Financial Results
From Optinose, Inc.
Via GlobeNewswire
Optinose to Present at the 2023 Cantor Global Healthcare Conference
From Optinose, Inc.
Via GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For August 21, 2023
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.